Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Covington
UBS
Fuji
US Department of Justice
Merck
Deloitte
Citi
QuintilesIMS
Cerilliant

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,968,976

« Back to Dashboard

Which drugs does patent 5,968,976 protect, and when does it expire?

Patent 5,968,976 protects FOSRENOL and is included in two NDAs.

This patent has thirty-five patent family members in twenty-seven countries.
Summary for Patent: 5,968,976
Title: Pharmaceutical composition containing selected lanthanum carbonate hydrates
Abstract:Selected lanthanum carbonate hydrates may be administered into the gastrointestinal tract, to treat hyperphosphataemia in patients with renal failure.
Inventor(s): Murrer; Barry A (Berkshire, GB), Powell; Nigel A (Berkshire, GB)
Assignee: AnorMed Inc. (Langley, CA)
Application Number:08/913,960
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Process; Formulation;

Drugs Protected by US Patent 5,968,976

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc FOSRENOL lanthanum carbonate POWDER;ORAL 204734-002 Sep 24, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE ➤ Subscribe
Shire Dev Llc FOSRENOL lanthanum carbonate POWDER;ORAL 204734-001 Sep 24, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE ➤ Subscribe
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-004 Nov 23, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y REDUCTION OF SERUM PHOSPHATE ➤ Subscribe
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-001 Oct 26, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y REDUCTION OF SERUM PHOSPHATE ➤ Subscribe
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-002 Oct 26, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y REDUCTION OF SERUM PHOSPHATE ➤ Subscribe
Shire Llc FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-003 Nov 23, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe Y REDUCTION OF SERUM PHOSPHATE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,968,976

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9506126Mar 25, 1995
PCT Information
PCT FiledMarch 19, 1996PCT Application Number:PCT/GB96/00575
PCT Publication Date:October 03, 1996PCT Publication Number: WO96/30029

International Patents Family Members for US Patent 5,968,976

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 209923 ➤ Subscribe
Australia 4951496 ➤ Subscribe
Australia 702073 ➤ Subscribe
Brazil 9607926 ➤ Subscribe
Canada 2216437 ➤ Subscribe
China 1102393 ➤ Subscribe
China 1184428 ➤ Subscribe
Czech Republic 293494 ➤ Subscribe
Czech Republic 9703017 ➤ Subscribe
Germany 122007000022 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
US Army
QuintilesIMS
Healthtrust
McKinsey
AstraZeneca
US Department of Justice
Dow
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot